-

10:43:29 PM

OKYO Stock News

OKYO - OKYO Pharma Limited

12/01/22 2:00 AM

Nasdaq : OKYO

OKYO Pharma Limited - Change of Auditor

OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in the multi-billion-dollar dry eye disease market,

RHEA-AI

neutral

11/24/22 2:00 AM

Nasdaq : OKYO

OKYO Pharma Limited – PDMR dealing

OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in the multi-billion-dollar market, announces that the

RHEA-AI

neutral

11/10/22 6:00 AM

Nasdaq : OKYO

OKYO Pharma Hosting Key Opinion Leader Event Introducing OK-101 as a Potential Treatment for Dry Eye Disease

OKYO Pharma Ltd (Nasdaq: OKYO; LSE: OKYO) (“OKYO” or the “Company”), an ophthalmology bio-pharmaceutical company focusing on the discovery and development of the novel molecule OK-101 to treat

RHEA-AI

neutral

09/08/22 9:25 AM

Nasdaq : OKYO

OKYO Pharma Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report®

OKYO Pharma Limited (NASDAQ: OKYO; LSE: OKYO;), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, today announces that an interview with its CEO, Dr

RHEA-AI

neutral

09/08/22 9:00 AM

Nasdaq : OKYO

OKYO Pharma Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

OKYO Pharma Limited (NASDAQ:OKYO); (LSE:OKYO), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, today announces that an interview with its CEO, Dr Gary Jacob

RHEA-AI

neutral

09/07/22 9:00 AM

Nasdaq : OKYO

OKYO Pharma Limited: Result of Annual General Meeting

The board of directors of OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), a bio-pharmaceutical company focused on developing an innovative approach to dry eye care and ocular pain, is pleased to announce that at the Annual General Meeting ("

RHEA-AI

neutral

08/30/22 2:00 AM

Nasdaq : OKYO

clinical trial

OKYO Pharma Plans Q4 2022 IND Filing of OK-101 to treat Dry Eye Disease with Subsequent Phase 2 Initiation Alongside Peptide Manufacturing Partner, AmbioPharm

OK-101 to treat ocular diseases, including Dry Eye Disease (DED), uveitis, allergic conjunctivitis, and ocular pain. Successful pre-IND meeting with FDA in Q1 2022 and novel speed to market potential. IND filing on OK-101 to treat DED planned for Q4 2022, with first human trial designed as Phase 2

RHEA-AI

very positive

08/16/22 2:00 AM

Nasdaq : OKYO

OKYO Pharma Limited - Final audited results for the year ended 31 March 2022

OKYO Pharma Limited (NASDAQ: OKYO; LSE: OKYO) (the “Company”) is pleased to announce its final audited results for the year ended 31 March 2022. Summary of OKYO-101 studies during the last year OK-101 is designed to target a chemokine-like

RHEA-AI

neutral

06/09/22 2:00 AM

Nasdaq : OKYO

OKYO Pharma Limited - PDMR Dealing

OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), a bio-pharmaceutical company focused on developing an innovative approach to dry eye care and ocular pain, today announces that it has been notified that Willy Simon, a non-executive director,

RHEA-AI

neutral

05/20/22 2:00 AM

OTC, Nasdaq : EMMLF, OKYO

OKYO Pharma Limited - PDMR Dealing

OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), a life sciences company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, today announces that it has been notified that Panetta

RHEA-AI

neutral